Brown Advisory Inc. Increases Stock Holdings in Avanos Medical, Inc. (NYSE:AVNS)

Brown Advisory Inc. raised its position in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 12.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,905,094 shares of the company's stock after buying an additional 204,218 shares during the period. Brown Advisory Inc. owned about 4.15% of Avanos Medical worth $30,329,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AVNS. Barclays PLC grew its position in Avanos Medical by 446.2% in the third quarter. Barclays PLC now owns 96,194 shares of the company's stock valued at $2,311,000 after purchasing an additional 78,583 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Avanos Medical by 15.8% during the fourth quarter. Envestnet Asset Management Inc. now owns 128,567 shares of the company's stock worth $2,047,000 after buying an additional 17,504 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Avanos Medical by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 5,339,778 shares of the company's stock worth $85,009,000 after buying an additional 19,476 shares during the period. JPMorgan Chase & Co. boosted its position in Avanos Medical by 6.9% during the third quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company's stock valued at $1,672,000 after acquiring an additional 4,472 shares during the last quarter. Finally, Empowered Funds LLC increased its stake in shares of Avanos Medical by 141.3% in the 4th quarter. Empowered Funds LLC now owns 153,834 shares of the company's stock valued at $2,449,000 after acquiring an additional 90,091 shares in the last quarter. 95.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Avanos Medical from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th.

Insiders Place Their Bets

In other news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the completion of the sale, the senior vice president now directly owns 82,047 shares of the company's stock, valued at $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.64% of the company's stock.

Avanos Medical Price Performance

Shares of AVNS stock traded up $0.07 during trading hours on Friday, reaching $12.65. The stock had a trading volume of 406,766 shares, compared to its average volume of 348,361. The firm has a market capitalization of $581.94 million, a PE ratio of 37.21 and a beta of 1.13. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The stock's fifty day simple moving average is $13.43 and its 200 day simple moving average is $16.03. Avanos Medical, Inc. has a 12 month low of $11.84 and a 12 month high of $25.36.

Avanos Medical (NYSE:AVNS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.07. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company had revenue of $167.50 million for the quarter, compared to analysts' expectations of $161.75 million. During the same quarter last year, the company earned $0.22 EPS. The firm's revenue was up .8% compared to the same quarter last year. On average, equities research analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.